fatty liver disease
fatty liver disease
Explore linked clinical trials. Standard reference: MONDO:0004790385 results · Page 1 of 16
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 2 | 2026-10-09 | NCT07288138 | |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-08 | NCT07165028 | |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | Digestive System Diseases, Digestive System Neoplasms, Fibrosis, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, epithelial neoplasm, fatty liver disease, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-10-08 | NCT06096779 | |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 2 | 2026-10-08 | NCT05519475 | |
| Blood Collection Biorepository for Liver Disease Research | Blood-Borne Infections, Body Weight, DNA Virus Infections, Digestive System Diseases, Fibrosis, Flaviviridae infectious disease, Hepadnaviridae infectious disease, Infections, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pediatric Obesity, RNA Virus Infections, Signs and Symptoms, cirrhosis of liver, fatty liver disease, hepatitis, hepatitis B virus infection, hepatitis C virus infection, infectious disease, liver disorder, metabolic dysfunction-associated steatotic liver disease, nutritional disorder, obesity disorder, overnutrition, viral hepatitis, viral infectious disease | Recruiting | Not stated | 2026-10-08 | NCT03025074 | |
| Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD | Body Weight, Chronic Disease, Digestive System Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, diabetes mellitus, endocrine system disorder, fatty liver disease, glucose metabolism disease, kidney disorder, kidney failure, liver disorder, metabolic disease, nutritional disorder, obesity disorder, overnutrition, urinary system disorder | Recruiting | Not stated | 2026-10-07 | NCT07187830 | |
| Biomarkers of Steatohepatitis in Type 2 Diabetes Patients | Digestive System Diseases, Nutritional and Metabolic Diseases, Steatohepatitis, diabetes mellitus, endocrine system disorder, fatty liver disease, glucose metabolism disease, liver disorder, metabolic disease | Active, not recruiting | Not stated | 2026-10-07 | NCT07098520 | |
| Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV | Blood-Borne Infections, Digestive System Diseases, Fibrosis, Genital Diseases, HIV infectious disease, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, Urogenital Diseases, cirrhosis of liver, fatty liver disease, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, liver disorder, metabolic dysfunction-associated steatotic liver disease, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Not yet recruiting | Not stated | 2026-10-06 | NCT07861594 | |
| Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder | Not yet recruiting | Not stated | 2026-10-06 | NCT07860814 | |
| NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP) | Chronic Disease, Digestive System Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infarction, Male Urogenital Diseases, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, fatty liver disease, glucose metabolism disease, heart disorder, ischemic disease, kidney disorder, kidney failure, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, type 2 diabetes mellitus, urinary system disorder, vascular disorder | Recruiting | Not applicable | 2026-10-06 | NCT07820800 | |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Digestive System Diseases, Fibrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-05 | NCT06419374 | |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Digestive System Diseases, Fibrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-05 | NCT06318169 | |
| Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Body Weight, Digestive System Diseases, Fibrosis, Insulin Resistance, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cirrhosis of liver, fatty liver disease, glucose metabolism disease, hyperinsulinism, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Phase 3 | 2026-10-02 | NCT07854782 | |
| A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 3 | 2026-09-30 | NCT07704892 | |
| A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 3 | 2026-09-30 | NCT07701993 | |
| A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 2 | 2026-09-29 | NCT07527910 | |
| Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States | Chemically-Induced Disorders, Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, alcohol-induced disorders, alcohol-related disorders, alcoholic liver cirrhosis, alcoholic liver disease, cirrhosis of liver, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease, substance-related disorder | Recruiting | Phase 2 | 2026-09-28 | NCT05832229 | |
| Early Tracking of Childhood Health Determinants (ETCHED) Study | Body Weight, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, fatty liver disease, glucose metabolism disease, liver disorder, metabolic disease, nutritional disorder, obesity disorder, overnutrition | Recruiting | Not stated | 2026-09-28 | NCT03481829 | |
| Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 4 | 2026-09-23 | NCT07718126 | |
| A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-09-23 | NCT07581951 | |
| Diagnosis and Quantification of Hepatic Steatosis Using Near-infrared Spectroscopy | Digestive System Diseases, Steatohepatitis, fatty liver disease, liver disorder | Not yet recruiting | Not applicable | 2026-09-23 | NCT07254533 | |
| Nutritional Indices and Inflammatory Markers in MASLD | Digestive System Diseases, Fibrosis, Fibrosis, Liver, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease, nutritional deficiency disease, nutritional disorder | Not yet recruiting | Not stated | 2026-09-22 | NCT07834905 | |
| Misocholic Tablets for Non-Viral Elevated Liver Enzymes | Chemically-Induced Disorders, Digestive System Diseases, Drug-Related Side Effects and Adverse Reactions, drug-induced liver injury, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease, poisoning | Not yet recruiting | Phase 3 | 2026-09-22 | NCT07833514 | |
| Metaboic Syndrome and Fatty Liver in Celiac Disease Females: Reponse to Exercise in Adolescents | Digestive System Diseases, Insulin Resistance, Nutritional and Metabolic Diseases, celiac disease, digestive system disorder, fatty liver disease, glucose metabolism disease, hyperinsulinism, intestinal disorder, liver disorder, malabsorption syndrome, metabolic disease, metabolic dysfunction-associated steatotic liver disease | Recruiting | Not applicable | 2026-09-22 | NCT07832994 | |
| Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 2 | 2026-09-22 | NCT06133101 |